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Isothiazolinones are used as biocides in a wide vari-
ety of products, such as cosmetics, detergents, and
industrial products. In the 1980s, a formulation with
methylchloroisothiazolinone (MCI) and methylisothia-
zolinone (MI) was responsible for an allergic contact
dermatitis ‘epidemic’. To control this phenomenon, a
maximum allowed dose was set. However in 2005, MI
alone was introduced in cosmetics, and this was followed
by a new ‘epidemic’ of sensitization to MI and MCI/MI (1).
We performed a retrospective study, consulting the
medical files of patch tested patients reactive to ISs,
from 2005 to 2013. MCI/MI was tested at 100 ppm in
water (TROLAB® patch test allergens, Almirall Hermal
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Fig. 1. Positive patch test sensitization to
methylchloroisothiazolinone/methylisothiazolinone (MI) or MI,
with MI being tested since May 2012.
GmbH, Reinbek, Germany) and MI was tested, from
May 2012, at 500 ppm in water (0.05%) (TROLAB®
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Fig. 2. Positive patch test reactions to methylchloroisothiazolinone
(MCI)/methylisothiazolinone (MI) and MI. IS, isothiazolinone.
patch test allergens). Allergens were applied for 48 hr
on the back, with Finn Chambers® on Scanpor® tape
(Epitest Ltd, Vellinge, Sweden), or IQ Ultra Chambers™
(Chemotechnique, Vellinge, Sweden). The readings were
performed on D2 or D3 and D4 or D7.
We observed a significant increase in isothiazolinone
sensitization. The prevalence rose from < 1% in 2005 to
3.24% in 2008. After 2012, and with the addition of the
MI patch test, the sensitization rates increased to 5.15%
in 2012, and doubled to 10.9% in the first half of 2013
(Fig. 1).
After 2011, we observed a total of 35 patients
with positive reactions to isothiazolinones, 20% men
(n = 7) and 80% women (n = 28), ranging in age
from 3 to 72 years. The percentage of patients with
an isothiazolinone-positive patch test reaction in the
different semesters is shown in Fig. 2. Definitive relevance
was established in 33 (94.3%) patients, mostly to
cosmetics and occupational activities. Eighteen cases
(51.4%) were related to professional activity (6 nurses, 3
hairdressers, a beautician, 5 cleaners or workers who also
clean their workplaces, and 2 factory workers). 15/35
(42.9%) patients had a positive patch test reaction to a
personal product containing isothiazolinones. To better
evaluate the clinical implications of IS sensitization, we
contacted by telephone 11 of 20 patients in whom a
causal relationship with products that were contacted
daily was not positively traced, and 10 reported clinical
improvement after avoiding isothiazolinone-containing
products. Moreover, 2 hairdressers changed their job
because of clinically severe symptomatology.
Discussion
The rate of isothiazolinone sensitization in our population
has been increasing consistently since 2005; this increase
was more pronounced in 2012, when the MI patch test
was introduced. Moreover, we observed 8 of 28 cases
reacting exclusively to MI; therefore, this patch test was
essential for the diagnosis of isothiazolinone sensitization
in 28.6% of patients.
The permitted concentration of MI in Europe should
be urgently revised. In an MI-sensitized population, 64%
reacted to products containing 50 ppm, whereas only
18% reacted to products containing 5 ppm (2). Definite
clarification of the primary sensitizer requires testing
with MCI and MI separately (3, 4, 5). However, in our
study, the asymmetrical patterns of reactivity to MI and
MCI/MI, and the higher intensity of the reactions (usually
greater intensity for MI than for MCI/MI), support primary
sensitization to MI in numerous cases.
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